LDL-C Optimization Using Inclisiran in Patients in Which Drug-Drug Interactions Limit LDL Lowering
A phase 4 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 100 participants.
Also called NCT06865885
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose treatment
- Phase
- Phase 4
- Enrolled
- 100 participants
- Registry
-
NCT06865885
-
- Started
- (actual)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- United States
- Registry status
- Recruiting
Technical summary
Registry record NCT06865885. Randomized; no masking; primary purpose treatment. Start 2025-04-02 (actual); primary completion 2028-06-01 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- LDL-C Optimization Using Inclisiran in Patients in Which Drug-Drug Interactions Limit LDL Lowering
- Acronym
- SOLVE-LDL-C
- Condition
- Drug Interactions
- Condition
- Primary Prevention
- Condition
- Cardiometabolic Syndrome
- Condition
- LDL-Cholersterol Lowering
- Condition
- Polypharmacy
- Intervention (Drug)
- Inclisiran sodium 300 mg (equivalent to 284 mg inclisiran) in 1.5 mL
- Lead sponsor
- University of California, San Diego
- Collaborator
- Novartis
Record details
- Record id
cardio:ct-nct06865885- Content hash
cb2af4e86dd4741fca81d5c467e0f1ec14dacf635667591cf120573a5a00b08f